4-[4-[2-[2-[Bis(4-chlorophenyl)methoxy]ethylsulfonyl]ethoxy]phenyl]-1,1,1-trifluoro-2-butanone | 221914-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-[2-[2-[Bis(4-chlorophenyl)methoxy]ethylsulfonyl]ethoxy]phenyl]-1,1,1-trifluoro-2-butanone
• 英文别名: 2-Butanone, 4-(4-(2-((2-(bis(4-chlorophenyl)methoxy)ethyl)sulfonyl)ethoxy)phenyl)-1,1,1-trifluoro-；4-[4-[2-[2-[bis(4-chlorophenyl)methoxy]ethylsulfonyl]ethoxy]phenyl]-1,1,1-trifluorobutan-2-one
• CAS: 221914-85-8
• 化学式: C₂₇H₂₅Cl₂F₃O₅S
• 分子量: 589.46
• InChiKey: IKQYQTPQMAIVQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  toluene-ethyl acetate 、 4-[4-[2-[2-[bis(4-chlorophenyl)methoxy]ethylthio]ethoxy]phenyl]-1,1,1-trifluoro-2-butanone 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以1.46 g (92%)的产率得到4-[4-[2-[2-[Bis(4-chlorophenyl)methoxy]ethylsulfonyl]ethoxy]phenyl]-1,1,1-trifluoro-2-butanone
  参考文献：
  名称：

  Trifluoromethyl ketone analogs as selective cPLA2 inhibitors

  摘要：

  选择性抑制cPLA2酶的抑制剂，可用于控制多种炎症性疾病。本发明提供的抑制剂具有以下通用公式

  公开号：

  US06255496B1

文献信息

• [EN] SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF<br/>[FR] DERIVE D'ACIDE ARYLALCANOIQUE SUBSTITUE ET SON UTILISATION
  申请人：ASAHI KASEI PHARMA CORP

  公开号：WO2005016862A1

  公开（公告）日：2005-02-24

  A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）。在该式中，Link代表一个由1至3个碳原子组成的饱和或不饱和直链烃链，芳环（E）中的C2至C6独立代表构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或者被Zx取代的碳原子，Zx代表由1至4个碳原子组成的饱和烷基基团等，Rs代表-D-Rx等，D代表单键、氧原子等，Rx代表由3至8个碳原子组成的饱和烷基基团等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子、由1至4个碳原子组成的低烷基基团等，或其盐。提供了一种具有抑制前列腺素产生和抑制白三烯产生作用的化合物。
• Substituted arylalkanoic acid derivatives and use thereof
  申请人：Shoda Motoshi

  公开号：US20070213333A1

  公开（公告）日：2007-09-13

  A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C 2 to C 6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）：[在公式中，Link代表饱和或不饱和的直链碳氢链，其具有1至3个碳原子，C2至C6在芳环（E）中独立地表示构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或被Zx取代的碳原子，Zx代表饱和的烷基基团，其具有1至4个碳原子等，Rs代表-D-Rx等，D代表单键，氧原子等，Rx代表饱和的烷基基团，其具有3至8个碳原子等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子，具有1至4个碳原子的低烷基基团等]或其盐。提供了一种具有前列腺素生成抑制作用和白三烯生成抑制作用的化合物。
• Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135383A1

  公开（公告）日：2007-06-14

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。具体地，本发明提供了一种用于治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及在胃肠道腔中定位的非吸收和/或外流的磷脂酶A2抑制剂的给药。
• SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1660427A1

  公开（公告）日：2006-05-31
• EP1660427A4
  申请人：——

  公开号：EP1660427A4

  公开（公告）日：2006-12-20